Does the media prefer ABVX or VRDN?

In the previous week, Abivax and Abivax both had 4 articles in the media. Abivax's average media sentiment score of 1.55 beat Viridian Therapeutics' score of 1.14 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Viridian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRDN or PRAX?

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 4 mentions for Viridian Therapeutics. Praxis Precision Medicines' average media sentiment score of 1.41 beat Viridian Therapeutics' score of 1.14 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRDN or KYMR?

In the previous week, Viridian Therapeutics and Viridian Therapeutics both had 4 articles in the media. Viridian Therapeutics' average media sentiment score of 1.14 beat Kymera Therapeutics' score of 0.95 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRDN or IONS?

In the previous week, Ionis Pharmaceuticals had 23 more articles in the media than Viridian Therapeutics. MarketBeat recorded 27 mentions for Ionis Pharmaceuticals and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.14 beat Ionis Pharmaceuticals' score of 0.34 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 4 Very Positive mention(s) 8 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PTGX or VRDN?

In the previous week, Protagonist Therapeutics had 8 more articles in the media than Viridian Therapeutics. MarketBeat recorded 12 mentions for Protagonist Therapeutics and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.14 beat Protagonist Therapeutics' score of 0.61 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viridian Therapeutics (VRDN) Competitors

$21.24 -1.05 (-4.71%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$20.74 -0.50 (-2.38%)

As of 09/11/2026 07:54 PM Eastern

Compare

VRDN vs. ABVX, PRAX, KYMR, IONS, and PTGX

Should you buy Viridian Therapeutics stock or one of its competitors? Viridian Therapeutics's main competitors and comparable companies include Abivax (ABVX), Praxis Precision Medicines (PRAX), Kymera Therapeutics (KYMR), Ionis Pharmaceuticals (IONS), and Protagonist Therapeutics (PTGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Viridian Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

47.9% of Abivax shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Abivax and Abivax both had 4 articles in the media. Abivax's average media sentiment score of 1.55 beat Viridian Therapeutics' score of 1.14 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Viridian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax presently has a consensus target price of $156.38, indicating a potential upside of 31.81%. Viridian Therapeutics has a consensus target price of $38.54, indicating a potential upside of 81.44%. Given Viridian Therapeutics' higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Abivax has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Viridian Therapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Viridian Therapeutics	$71.13M	33.83	-$342.60M	-$3.37	N/A

Abivax has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Viridian Therapeutics' return on equity of -72.97% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

Summary

Viridian Therapeutics beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Viridian Therapeutics compare to Praxis Precision Medicines?

Viridian Therapeutics (NASDAQ:VRDN) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Praxis Precision Medicines has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Praxis Precision Medicines' return on equity of -34.15% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Praxis Precision Medicines has lower revenue, but higher earnings than Viridian Therapeutics. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$71.13M	33.83	-$342.60M	-$3.37	N/A
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$12.93	N/A

67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Viridian Therapeutics presently has a consensus price target of $38.54, indicating a potential upside of 81.44%. Praxis Precision Medicines has a consensus price target of $585.95, indicating a potential upside of 75.13%. Given Viridian Therapeutics' higher probable upside, equities research analysts clearly believe Viridian Therapeutics is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.95

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 4 mentions for Viridian Therapeutics. Praxis Precision Medicines' average media sentiment score of 1.41 beat Viridian Therapeutics' score of 1.14 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viridian Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market.

Summary

Praxis Precision Medicines beats Viridian Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to Kymera Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Viridian Therapeutics currently has a consensus target price of $38.54, indicating a potential upside of 81.44%. Kymera Therapeutics has a consensus target price of $130.83, indicating a potential upside of 13.81%. Given Viridian Therapeutics' higher possible upside, research analysts plainly believe Viridian Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.88

Kymera Therapeutics has higher revenue and earnings than Viridian Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$71.13M	33.83	-$342.60M	-$3.37	N/A
Kymera Therapeutics	$105M	91.04	-$311.35M	-$3.24	N/A

Viridian Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

Kymera Therapeutics has a net margin of -285.33% compared to Viridian Therapeutics' net margin of -505.86%. Kymera Therapeutics' return on equity of -21.22% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

In the previous week, Viridian Therapeutics and Viridian Therapeutics both had 4 articles in the media. Viridian Therapeutics' average media sentiment score of 1.14 beat Kymera Therapeutics' score of 0.95 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kymera Therapeutics beats Viridian Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Viridian Therapeutics compare to Ionis Pharmaceuticals?

Viridian Therapeutics (NASDAQ:VRDN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Viridian Therapeutics currently has a consensus target price of $38.54, suggesting a potential upside of 81.44%. Ionis Pharmaceuticals has a consensus target price of $91.25, suggesting a potential upside of 68.33%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Ionis Pharmaceuticals has a net margin of -64.76% compared to Viridian Therapeutics' net margin of -505.86%. Viridian Therapeutics' return on equity of -72.97% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

In the previous week, Ionis Pharmaceuticals had 23 more articles in the media than Viridian Therapeutics. MarketBeat recorded 27 mentions for Ionis Pharmaceuticals and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.14 beat Ionis Pharmaceuticals' score of 0.34 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	4 Very Positive mention(s)	8 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Viridian Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$71.13M	33.83	-$342.60M	-$3.37	N/A
Ionis Pharmaceuticals	$944M	9.54	-$381.39M	-$3.46	N/A

Viridian Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Summary

Viridian Therapeutics beats Ionis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Viridian Therapeutics (NASDAQ:VRDN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Protagonist Therapeutics has a net margin of 29.40% compared to Viridian Therapeutics' net margin of -505.86%. Protagonist Therapeutics' return on equity of 12.03% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

In the previous week, Protagonist Therapeutics had 8 more articles in the media than Viridian Therapeutics. MarketBeat recorded 12 mentions for Protagonist Therapeutics and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.14 beat Protagonist Therapeutics' score of 0.61 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics presently has a consensus target price of $147.13, indicating a potential downside of 0.71%. Viridian Therapeutics has a consensus target price of $38.54, indicating a potential upside of 81.44%. Given Viridian Therapeutics' higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Protagonist Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Protagonist Therapeutics has higher earnings, but lower revenue than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	208.36	-$130.15M	$1.03	143.86
Viridian Therapeutics	$71.13M	33.83	-$342.60M	-$3.37	N/A

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Protagonist Therapeutics beats Viridian Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRDN vs. The Competition

Export

Metric	Viridian Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.53B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-6.30	14.25	275.24	25.29
Price / Sales	33.83	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	3.44	15.12	10.33	6.20
Net Income	-$342.60M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-7.33%	-4.34%	-3.32%	-2.35%
1 Month Performance	-7.17%	-0.02%	-0.41%	-2.77%
1 Year Performance	12.56%	40.64%	19.21%	7.63%

Viridian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRDN Viridian Therapeutics	2.8635 of 5 stars	$21.24 -4.7%	$38.54 +81.4%	+8.1%	$2.53B	$71.13M	N/A	252	Positive News
ABVX Abivax	2.6108 of 5 stars	$114.79 flat	$156.50 +36.3%	+38.0%	$10.02B	N/A	N/A	61	News Coverage Positive News Analyst Upgrade
PRAX Praxis Precision Medicines	3.0013 of 5 stars	$351.81 flat	$585.95 +66.6%	+748.8%	$9.82B	$8.55M	N/A	110	News Coverage Positive News
KYMR Kymera Therapeutics	1.8089 of 5 stars	$117.39 flat	$128.70 +9.6%	+148.8%	$9.76B	$39.21M	N/A	170	Analyst Upgrade
IONS Ionis Pharmaceuticals	3.1981 of 5 stars	$58.09 flat	$92.95 +60.0%	-15.3%	$9.65B	$944M	N/A	1,402	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRDN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viridian Therapeutics (VRDN) Competitors

VRDN vs. ABVX, PRAX, KYMR, IONS, and PTGX

How does Viridian Therapeutics compare to Abivax?

Summary

How does Viridian Therapeutics compare to Praxis Precision Medicines?

Summary

How does Viridian Therapeutics compare to Kymera Therapeutics?

Summary

How does Viridian Therapeutics compare to Ionis Pharmaceuticals?

Summary

How does Viridian Therapeutics compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viridian Therapeutics (VRDN) Competitors

VRDN vs. ABVX, PRAX, KYMR, IONS, and PTGX

How does Viridian Therapeutics compare to Abivax?

Do insiders & institutionals believe in ABVX or VRDN?

Does the media prefer ABVX or VRDN?

Do analysts rate ABVX or VRDN?

Which has more volatility & risk, ABVX or VRDN?

Which has preferable valuation and earnings, ABVX or VRDN?

Is ABVX or VRDN more profitable?

Summary

How does Viridian Therapeutics compare to Praxis Precision Medicines?

Is VRDN or PRAX more profitable?

Which has higher valuation and earnings, VRDN or PRAX?

Do insiders and institutionals hold more shares of VRDN or PRAX?

Do analysts rate VRDN or PRAX?

Does the media refer more to VRDN or PRAX?

Which has more risk and volatility, VRDN or PRAX?

Summary

How does Viridian Therapeutics compare to Kymera Therapeutics?

Do analysts rate VRDN or KYMR?

Which has stronger earnings & valuation, VRDN or KYMR?

Which has more volatility & risk, VRDN or KYMR?

Is VRDN or KYMR more profitable?

Does the media refer more to VRDN or KYMR?

Summary

How does Viridian Therapeutics compare to Ionis Pharmaceuticals?

Do analysts prefer VRDN or IONS?

Is VRDN or IONS more profitable?

Does the media refer more to VRDN or IONS?

Do institutionals and insiders have more ownership in VRDN or IONS?

Which has stronger earnings & valuation, VRDN or IONS?

Which has more risk & volatility, VRDN or IONS?

Summary

How does Viridian Therapeutics compare to Protagonist Therapeutics?

Is PTGX or VRDN more profitable?

Does the media prefer PTGX or VRDN?

Do analysts recommend PTGX or VRDN?

Which has more volatility and risk, PTGX or VRDN?

Which has preferable earnings and valuation, PTGX or VRDN?

Do institutionals & insiders believe in PTGX or VRDN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools